SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News:
Aerocrine AB (OMX Nordic Exchange: AERO) (STO:AEROB) today announced that trading in the Company’s shares was halted in response to speculation regarding the publication of U.S. guidelines regarding the Company’s method.
The company wants to clarify that no official publication of the expected U.S.guidelines regarding inflammation monitoring has been made by the ATS (American Thoracic Society).
